Certican Prevention of organ 2011 III rejection – liver DEB025 Hepatitis C 2013 II - Phase III start planned in Q4 2010 Exjade Non transfusion 2011 II dependent Thalassemia HCD122 Hematological tu
mors ≥2014 I INC424 Myelofibrosis 2011 III - Results from a Phase I/II study published in The New England Journal of Medicine in September showed approximately 7
5% of myelofibrosis patients receiving INC424 twice-daily experienced rapid reduction in spleen size, which was durable
...[+++]for more than one year of follow-up